Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs

Bulletin Express

03/12

Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.

The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.

Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.

The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1179340994"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179340994\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179340994?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179340994","market":"us","top_or_hot":-1,"title":"Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs","media":"Bulletin Express","content":"<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.</p>\n<p>The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.</p>\n<p>Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.</p>\n<p>The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Bio (01877) Fully Returns RMB1.11 Billion of Idle Proceeds Previously Deployed for Working-Capital Needs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.</p>\n<p>The company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.</p>\n<p>Management confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.</p>\n<p>The board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1179340994","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179340994","pubTimestamp":1773315771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"君实生物(01877)全额返还此前用于营运资金需求的闲置募集资金11.1亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio, HKEX: 01877; SSE: 688180) has announced the complete return of RMB1.11 billion in idle IPO proceeds that had been temporarily allocated to bolster liquidity.\nThe company’s board approved the temporary use of idle funds on 27 March 2025, authorising up to RMB2.00 billion for business expansion, daily operations and production activities for a period not exceeding 12 months. Within this mandate, Junshi Bio utilised RMB1.11 billion.\nManagement confirmed that the drawdown did not disrupt the timeline of any capital-expenditure projects financed by the original proceeds. All borrowed funds were redeposited into the dedicated proceeds account by 12 March 2026, and the move has been disclosed to the company’s sponsor and sponsor representative.\nThe board reiterates that the transactions complied with Shanghai Stock Exchange regulations and internal controls governing the use and restitution of offering proceeds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}